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The short-term tests to detect carcinogens
can be grouped as follows:
1. Those that can be used to determine
carcinogenic potential.
(a) Microbial mutation tests which include
auxiliary metabolism of the test com-
pound by a fraction of mammalian
liver homogenate.
(i) Bacterial forward and reverse
mutation;
(ii) Yeast and fungal mutation, gene
conversion, mitotic recombination
or non-disjunction;
(iii) DNA damage and repair including
chromosome damage;
(iv) Mammalian cell mutation; and
(v) Mammalian cell transformation.
(b) Non-mutation-based tests.
(i) Mouse skin sebaceous gland sup-
pression;
(ii) Degranulation of the rough endo-
plasmic reticulum of rat liver cell.
2. Whole-mammal tests which can aid in
assessing carcinogenic hazard when con-
ventional carcinogen testing data in ani-
mals are absent.
(i) DNA binding oflabelled chemical;
(ii) Host-mediated assays where micro-
organisms are used to test the
mutagenicity of a chemical after
parenteral application;
(iii) Sperm morphology;
(iv) Mammalian hair spot test (after
treatment in utero);
(v) Dominant-lethal test in mice;
(vi) Heritable-translocation test in mice;
(vii) Biochemical detection of somatic
cell mutation; and
(viii) In vivo cytogenetics in somatic and
germ cells.
Structure/activity
In addition to the above testing procedures
a consideration of the relation between
structure and activity is essential if indis-
criminate and wasteful screening is to be
avoided. The precision of a test can be
improved by the selection of an appropriate
chemical-class control compound. Knowledge
of the metabolism of a group of compounds
and the responses given by the chemicals to
a variety ofshort-term tests is valuable when
the most effective assay is to be selected and
when test results are interpreted.
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THE THEORY of two-stage carcinogenesis
involving initiation and promotion was
developed by Berenblum (Berenblum, 1974)
and the experimental data on carcinogenesis
in mouse skin which he and his colleagues
produced in the 1940s and 1950s still provide
the factual basis which underpins current
concepts ofmulti-stage carcinogenesis. Multi-
stage models in which the promoting phase
is further divided into two or more stages are
required to explain the epidemiological data
on time-related tumour incidence in man, and
they also apply to experimental carcino-
genesis both in skin and other organs, in-
cluding the liver and bladder.
Multi-stage carcinogenesis in the bladder
involves first a permanent transformation of
cells in the transitional epithelium (uro-
thelium) into latent tumour cells by a thres-
hold or sub-threshold dose of a bladder
carcinogen such as N-methyl-N-nitrosourea
(MNU) N-butyl-N-(4-hydroxybutyl) nitro-
samine (BBN) or N-(4-(5-nitro-2-furyl)-2-
thiazolyl) formamide (FANFT). The initiated
cells may then be converted into tumour
cells by further exposure to the same or
another carcinogen which is organotropic for
the urothelium, or by prolonged application
of a promoter which itselfis not effective as a
complete (initiating+promoting) carcinogen.
In the bladder, saccharin, cyclamate, trypto-
phan and cyclophosphamide all behave
predominantly as promoters. Development of
a visible growing tumour from the promotedBRITISH ASSOCIATION FOR CANCER RESEARCH 505
cells may then be accelerated by other
hyperplastic agents such as bladder calculi
which, though they may not be able to
substitute for promoters in the early stages
of conversion of an initiated cell into a latent
tumour cell, will propagate subsequent tum-
our growth by stimulating the rate of cell
turnover in the transformed urothelium.
Berenblum noted: 1. that for an unequivo-
cal demonstration of a second, promoting
stage ofcarcinogenesis, the initiating carcino-
gen must be used at a dose which is not car-
cinogenic to any marked degree; 2. that
tumour incidence is related to the dose of
initiator, not to the dose ofpromoter; 3. that
initiation requires only brief exposure to the
carcinogen and that the change produced is
persistent; and 4. that promotion requires
prolonged application of the promoter, and
is reversible in its early stages.
These observations were made on the basis
ofmouse skin, but are also demonstrably true
for carcinogenesis in the urinary bladder.
Thus: 1. The effect of initiation with either
MNU or FANFT, used at threshold or sub-
threshold doses, is promoted by subsequent
prolonged feeding of saccharin or cyclamate
in the diet (Hicks et al., 1978; Cohen et al.,
1979). If, however, MNU is used at a dose
which produces a 40% incidence of bladder
tumours, no increase in tumour incidence is
produced by ingestion ofsweeteners, although
in the same experiment a 28% incidence of
urothelial tumours of the renal pelvis was
promoted to 57% by saccharin and to 43°%
by cyclamate (Mohr et al., 1978). This is
directly analogous to observations made with
mouse skin which showed that the tumour
incidence following a high carcinogenic dose
of benzo(a)pyrene could not be increased by
subsequent application of the promoter
croton oil (Berenblum, 1941). 2. In the blad-
der, after one particular sub-threshold initiat-
ing dose of MNU, the tumour incidence is
constant at - 50% following promotion with
either dietary saccharin or cyclamate, ir-
respective of the dose of sweetener (Hicks
et al., 1978). 3. For initiation with MNU, all
that is required is a single, intravesicle instal-
lation ofa low dose (- 0-2 mg) which, because
of the rate of spontaneous decomposition in
the body, probably persists in the bladder for
not more than 20-30 min. Initiation with
MNU has now been demonstrated to persist
for at least 6 months, and with FANFT for
at least 6 weeks, though with the latter com-
pound there is some reduction in the sub-
sequent tumour incidence which follows
promotion, suggesting the presence of effec-
tive excision repair in the urothelium. 4. No
promotion was obtained with a single dose of
cyclophosphamide after initiation with MNU
(Hicks et al., 1978) but prolonged dosing with
cyclophosphamide promoted tumour growth
following initiation with FANFT (Cohen
et al., 1979).
These findings, together with other experi-
mental data now available, support the hypo-
thesis that carcinogenesis in the urinary
bladder, as in the mouse skin, is a multi-stage
process involving initiation, promotion and
propagation.
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HEPATIC NODULAR LESIONS IN RATS AND MICE: THEIR
SIGNIFICANCE
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A WIDE RANGE of proliferative lesions has
been observed in the livers of both rats and
mice. The lesions range from undoubted
hepatocarcinomas to small foci of prolifera-
tive hepatocytes. Many lesions may occur
"spontaneously", whilst similar effects have
been described after chemical injury, dietary
manipulation or surgical intervention.